ERBB2 and breast cancer: It showed that elderly patients with HER2-positive breast cancer treated with trastuzumab monotherapy had outcomes comparable to those receiving trastuzumab plus chemotherapy, suggesting that trastuzumab alone may be a reasonable option in this setting.